https://doi.org/10.55788/f7a0c76f
Dr Zafer Tandoğdu (University College London, UK) presented data derived from the SERPENS study [1]. This prospective observational study of approximately 600 patients specifically looked at outcomes for urosepsis.
Defining diagnostic criteria in the sepsis field has been problematic, but most researchers now agree that a suspicion of infection coupled with a mental state assessment and either the Systemic Inflammatory Response Syndrome (SIRS) or the National Early Warning Score (NEWS) constitute the best approach for the identification of severe sepsis and septic shock. The susceptibility profile of each patient should be carefully evaluated at the baseline evaluation (diagnosis of urosepsis). Most patients will develop urosepsis within 10 days of an intervention. Many patients will have had previous urosepsis, previous hospitalisation, or are diabetic, and 43% will have had a recent urinary tract infection. Overall, about half of urosepsis patients have >1 comorbidity. Baseline catheter burden should be evaluated as well.
The 30-day outcomes from the SERPENS database indicated that mortality is reduced in urosepsis, at only 2.8% versus 20% other-source mortality. This reduction may be attributed to the fact that urosepsis is a less aggressive septic condition as compared with other septic sources (e.g. pneumonia or colorectal) because it is possible to gain local control relatively quickly. Among the patients who died, 75% had severe sepsis and 25% had SIRS/sepsis.
The clinical failure rate was 15%, of whom 77% had severe sepsis. Urosepsis patients carry a high burden of disease, including local and systemic damage, and 10-15% of patients will acquire a recurrent infection. The main determinants of clinical failure are age and comorbidities (e.g. Parkinson’s disease), catheter burden, acute kidney injury and resting respiratory rate, previous admissions and antibiotic treatments, and previous urinary tract infection burden.
Dr Tandoğdu commented on the current discussion in sepsis management of personalisation versus protocolisation. Although the concept ‘each hour saves lives’ has led to early administration of antibiotics, only 57%-80% of patients with suspicion of sepsis were proven to actually have sepsis [2]. In non-septic shock patients, there is a window of time to identify the pathogen and apply specific treatments. In another prospective observational study (n=679), 34% of patients received inappropriate antibiotics [3]. Despite the overuse of antibiotics, no impact on mortality was observed, and individual patient characteristics turned out to be more relevant to patient outcomes.
Dr Tandoğdu’s take-home message was: "Don’t delay antibiotics, but do use them cautiously and selectively."
- Tandoğdu Z, et al. EAU20 Virtual Congress, 17-26 July 2020, Plenary Session 02: New frontiers in infections.
- Klein Klouwenberg PM, et al. Crit Care. 2015;19(1):319.
- Fitzpatrick JM, et al. Clin Microbiol Infect. 2016;22(3):244-251.
Posted on
Previous Article
« EAU 2020 Highlights Podcast Next Article
New lithotripter data: improved stone clearance »
« EAU 2020 Highlights Podcast Next Article
New lithotripter data: improved stone clearance »
Table of Contents: EAU 2020
Featured articles
Surgical Techniques and Safety
The new adjustable artificial sphincter victo: Surgical technique and results after a follow-up of more than one year
New urosepsis data from the SERPENS study
Stones
Intra-operative cone-beam computed tomography for detecting residual stones in percutaneous nephrolithotomy
Pressure and temperature: do high-power lasers pose a threat?
Radiation stewardship for patient and endourologist
New lithotripter data: improved stone clearance
Renal Cancer
Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses
Imaging guided surgery with augmented reality for robotic partial nephrectomy
KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib
Debate: upfront cytoreductive nephrectomy or not?
Robotic-assisted partial nephrectomy: lower morbidity
Bladder Cancer
Reduced BCG frequency, faster NMIBC recurrence
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Understanding MIBC biology for novel treatment options
Prostate Cancer & Imaging
Transperineal laser ablation of prostate
Prostatectomy: R-LRPE better than LRPE for continence
PSMA PET-CT staging is 27% more accurate
Docetaxel + hormonal therapy: improved prostate cancer PFS
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups
Large patient-driven survey reveals QoL issues after prostate cancer treatment
Targeting steroid sulphatase in resistant prostate cancer cells
Good tolerance of post-RP radiotherapy ± short-term ADT
BPH & LUTS
Minimizing post-operative stress urinary incontinence after HoLEP: Our preliminary experience and short-term results of ‘’En Bloc’’ technique with early apical release
LUTS 2-year outcomes: aquablation versus TURP
HoLEP versus PVP in prospective randomised trial
Testis Cancer & Andrology
Peyronie’s disease: surgical options
Infertility and testis cancer risk: causal or association?
32% more men complain of reduced sex drive in 2019 versus 2009
Related Articles
October 23, 2020
Finerenone improves outcomes in chronic kidney disease with diabetes
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com